// App-Quantinova.ai

118 : Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.

Researchers

Presenter

  • Somnath Mukherjee

Principal Investigators

  • Chris Hurt

  • Stephen Falk

  • Simon Gollins

  • John Staffurth

  • Ruby Ray

  • John A. Bridgewater

  • David Cunningham

  • Jane M. Blazeby

  • Rajarshi Roy

  • Tim Maughan

  • Gareth Griffiths

  • Tom David Lewis Crosby

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Bristol Haematology and Oncology Centre, Bristol, United Kingdom

  • North Wales Cancer Treatment Centre, Bodelwyddan, United Kingdom

  • Velindre NHS Trust, Cardiff, United Kingdom

  • Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • University of Bristol, Bristol, United Kingdom

  • Castle Hill Hospital, Driffield, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

  • Erbitux

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved